Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Role of Recombinant Human Activated Protein C (Drotrecogin Alfa, Activated, Xigris®) for Severe Sepsis

Role of Recombinant Human Activated Protein C (Drotrecogin Alfa, Activated,... Severe sepsis is a common life-threatening disease commonly associated with systemic inflamma- tion and altered coagulation processes. Drotrecogin alfa (activated), (Xigris ) is a novel drug which has both anti-inflammatory and anticoagulant properties and was approved in 2001 for the reduction in mortality in patients with severe sepsis at a high risk of death. It is currently unclear which subset of patients with severe sepsis is most likely to benefit from this therapy; however, the most severely ill patient with multiple organ dysfunction appear to gain the most benefit. Key words: drotrecogin alfa activated, protein C, sepsis cians; however, a better understanding of the ESPITE advances in technology re- pathophysiology has allowed more rational, lated to critical care, sepsis contin- Dues to cause significant morbidity and evidenced-based algorithms to be developed. mortality. Approximately 750,000 cases of Specifically, an understanding of the contribu- sepsis occur each year in the United States tions of inflammatory mediators and proco- with an associated mortality of 25% to 70% agulant factors on the sepsis process has al- (25%–30% for severe sepsis and 40%–70% lowed for the research and development of for septic shock) and this number is only more targeted therapeutic agents. Drotreco- expected http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advanced Emergency Nursing Journal Wolters Kluwer Health

Role of Recombinant Human Activated Protein C (Drotrecogin Alfa, Activated, Xigris®) for Severe Sepsis

Loading next page...
 
/lp/wolters-kluwer-health/role-of-recombinant-human-activated-protein-c-lpar-drotrecogin-alfa-wKFwC3ALez
Copyright
© 2007 Wolters Kluwer Health | Lippincott Williams & Wilkins
ISSN
1931-4485
eISSN
1931-4493
DOI
10.1097/01.TME.0000286963.71416.73

Abstract

Severe sepsis is a common life-threatening disease commonly associated with systemic inflamma- tion and altered coagulation processes. Drotrecogin alfa (activated), (Xigris ) is a novel drug which has both anti-inflammatory and anticoagulant properties and was approved in 2001 for the reduction in mortality in patients with severe sepsis at a high risk of death. It is currently unclear which subset of patients with severe sepsis is most likely to benefit from this therapy; however, the most severely ill patient with multiple organ dysfunction appear to gain the most benefit. Key words: drotrecogin alfa activated, protein C, sepsis cians; however, a better understanding of the ESPITE advances in technology re- pathophysiology has allowed more rational, lated to critical care, sepsis contin- Dues to cause significant morbidity and evidenced-based algorithms to be developed. mortality. Approximately 750,000 cases of Specifically, an understanding of the contribu- sepsis occur each year in the United States tions of inflammatory mediators and proco- with an associated mortality of 25% to 70% agulant factors on the sepsis process has al- (25%–30% for severe sepsis and 40%–70% lowed for the research and development of for septic shock) and this number is only more targeted therapeutic agents. Drotreco- expected

Journal

Advanced Emergency Nursing JournalWolters Kluwer Health

Published: Jul 1, 2007

There are no references for this article.